




# CAR-T Congress USA

## Maximising the Potential of CAR-T Therapy

21st-22nd March 2018 | Hilton Boston Dedham Hotel | Boston, MA

With Commercialization Day on 20th March (separately bookable)

### Discover the potential of CAR-T

in solid  
tumors with  
break-through  
research

### Hear the novel protocols

from leaders  
in the industry  
working to shape  
the future of  
immuno-oncology

### Collaborate and partner

with leading  
figures &  
institutions  
with a dedicated  
commercialization  
day

### Discuss strategies to improve patient access

and improve  
the commercial  
viability of CAR-T  
therapies

**40+**  
SPEAKERS


**100+**  
ATTENDEES

**50:50**  
RATIO  
of Academics  
to Industry

**20+**  
1-TO-1  
Meetings Available  
per Attendee

**1**  
DEDICATED  
Poster  
Session

### Presenting Institutions:




Presented by:

**Kisaco  
Research**

Register: [www.car-tcongress.com](http://www.car-tcongress.com) • +44 (0)20 3696 2920

# TIMELINE OF CAR-T





# WHO YOU WILL MEET

THIS 2 DAY PROGRAM HAS BEEN DEVELOPED TO ADDRESS THE KEY AREAS OF DISCUSSION FOR:

- **ACADEMICS:**

Professors and R&D experts from world-leading institutions and Cancer centers, working in Cellular Therapeutics, Oncology, Immunology and Immuno-oncology

- **PHYSICIANS:**

Oncologists, Immunologists and Haematologists

- **PHARMACEUTICAL:**

CEOs, CSOs, Senior Management, Principal Scientists, Heads of CAR-T, Cell Therapy, Process Development, Non-Clinical Safety, Research and Development, Business Development and Strategic Teams

- **BIOTECHS:**

Founders of emerging companies and start-ups, CSOs, early to clinical stage cell therapy companies globally

- **SERVICE PROVIDERS:**

Consultants, CMOs, CROs

## GET INVOLVED

### POSTER PRESENTATIONS

Showcase your work to the cell therapy community with our dedicated poster sessions. Get involved and get your research noticed in the dedicated poster area. Poster presentations will run during breaks and at scheduled times alongside sessions.

**Submit your poster on our website**

**Deadline: 2nd March 2018**

### EMERGING COMPANY SHOWCASE

Are you an academic, early stage start-up or emerging company looking to commercialize your latest innovation and technology? You're invited to present the commercial opportunities of your development to investors looking to hear about the next big development.

**Apply on our website**

### MEETING MOJO

Collaboration and building relationships is at the core of the CAR-T Congress. In addition to the scheduled networking breaks, our 'MEETING MOJO' platform enables you to create a bespoke meeting schedule, ensuring you connect with those with similar interests.

**REGISTER TODAY**

### KEY SESSIONS:

- **Targeting, Control & Safety:** The development of safety switches and antigen discovery for solid tumors
- **Scalability & Automation:** Novel protocols to scale up production whilst ensuring quality is not compromised
- **Alternative CAR Constructs:** CAR-NK, CAR-Tregs, gamma delta CAR-T and the use of CARs on alternative cell types
- **Commercialisation, Regulation & Patient Access:** How to navigate the regulatory processes to create commercially viable treatments

## INTERESTED IN SPONSORSHIP OPPORTUNITIES?

Far from the typical 'meet-and-greet' exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list. With our extensive marketing experience and strategy, your partnership with the conference will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts.

Sponsorship opportunities include exhibition, presentations, branding and an innovation showcase. Get in touch to find out ways to get involved.

Contact **Ben Edwards** to find out more about each package by emailing [events@kisacoresearch.com](mailto:events@kisacoresearch.com) or by calling +44 (0)20 3696 2920

# COMMERCIALIZATION DAY



Take advantage of a dedicated day for collaboration and partnering. Networking opportunities will be enhanced with 1-to-1 meetings between academia, start-ups, spin-offs and those looking to invest and commercialize on emerging technologies. Hear first-hand experience of the investment process and most importantly meet the decision makers to discuss partnerships and opportunities to work together in the future.

## 10:00 – 10:15 **INTRODUCTORY TALK - THE CAR-T INDUSTRY LANDSCAPE**

An overview into recent developments & areas of growth

## 10:15 – 11:00 **DISCUSSION: CAR-T ACHIEVEMENTS & THE ROUTES TO COMMERCIALIZATION**

- What challenges need to be overcome before CAR-T can be a commercially viable therapy?
- How to identify emerging companies from pre-clinical data?
- Obstacles facing emerging companies

**Panellists:**

Karim Helmy, Vice President, **Venrock**

James Noble, CEO, **Adaptimmune**

## 11:00 -11:30 **NETWORKING BREAK**

## 11:30 – 12:00 **WORKSHOP**

- Intellectual Property: a CAR-T cell entrepreneur's experience
- Challenges of CAR-T cell commercialization

Ronald Dudek, **Living Pharma**

## 12:00 – 13:30 **LUNCH & MEETING MOJO NETWORKING BREAK**

## 13:30 – 14:30 **EMERGING COMPANY SHOWCASE**

An opportunity for four shortlisted emerging companies to present their new innovations  
Visit website to submit an application

## 14:30 – 15:00 **DISCUSSION: FROM BENCH TO BEDSIDE: TRANSLATING TECHNOLOGIES FROM CONCEPT TO REALITY**

- Collaborative approaches to research
- Identifying emerging technologies
- Defining objectives & strategies for commercialization
- Bridging the gap between industry & academia

**Panellists:**

Gary Sclar, **Dana Farber Innovations**

Michael Poisel, **Penn Center for Innovation**

## 15:00 – 16:00 **MEETING MOJO NETWORKING SESSION**

14:00-14:20 – meeting slot 1

14:20-14:40 – meeting slot 2

14:40-15:00 – meeting slot 3

## 16:00 **CHAIR'S CLOSING REMARKS**

# AGENDA DAY 1

## TARGETING, CONTROL & SCALABILITY



8:00-8:30

### REGISTRATION

8:30-8:45

### CHAIR'S OPENING REMARKS

8:45-9:20

### KEYNOTE: VERY RAPID MANUFACTURING OF GENETICALLY MODIFIED T CELLS FOR CANCER: HELPING TO SOLVE ISSUES OF COST AND SCALE UP

Laurence Cooper, Chief Executive Officer, **Ziopharm**

9:20-9:50

### DISCUSSION: THE RACE TO SOLID TUMOR TARGETING

- Will TCRs or bi-specific T-cell engagers overtake CAR-T?
- Can CAR-T have the same success in solid tumors as in hematological tumors?

Panellists:

Joern-Peter Halle, Senior Vice President, Head Translational Innovation Platform Immuno-Oncology and Head External Innovation

Neil Sheppard, Head External Co-operations & Early Development Leader, **GSK**

Robert Hofmeister, Chief Scientific Officer, **TCR2**

9:50-10:25

### OVERCOMING THE CHALLENGES & COMPLEXITIES OF THE PERSONALIZED MEDICINE SUPPLY CHAIN

Scott Ohanesian, Senior VP, Commercial Operations, **QuickSTAT**

10:25 – 11:00

### NETWORKING BREAK & POSTER PRESENTATIONS

#### STREAM 1: TARGETING, DELIVERY & CONTROL

11:00 – 11:35

#### TARGETING MULTIPLE MYELOMA WITH NEXT GENERATION CAR-T CELL THERAPIES

Blythe Sather, Associate Director, **Juno Therapeutics**

11:35 – 12:10

#### DEVELOPING MOLECULAR CONTROL SWITCHES FOR CAR-T IN TARGETING SOLID TUMORS

Matthew Hewitt, Principal Scientist/Director, Tumor Microenvironment, **Bellicum Pharmaceuticals**

12:10 – 12:45

#### TARGETING MOLECULES FOR SOLID TUMORS

Dr Bijal Shah, MD Medical Oncology, **Moffitt Cancer Center**

12:45 -14:20

### LUNCH & NETWORKING BREAK

14:20 -14:50

#### PREDICTING TUMOR-SPECIFIC NEOANTIGENS FROM SEQUENCE DATA – DRIVING PERFORMANCE WITH MACHINE LEARNING

Andrew Allen, President & CEO, **Gritstone Oncology**

#### STREAM 2: SCALABILITY, MANUFACTURING & PROCESS DEVELOPMENT

#### MICROFLUIDIC TOOLS TO STREAMLINE CELL THERAPY PROCESSING

Jason Fierings, Distinguished Technical Staff, **Draper Lab**

#### PARTNER SPOTLIGHT SESSION

Contact Ben Edwards to find out more by emailing [events@kisacoresearch.com](mailto:events@kisacoresearch.com) or by calling: +44 (0)20 3696 2924

#### ENGINEERING PLURIPOTENT CELLS FOR OFF-THE-SHELF CANCER IMMUNOTHERAPY

Bob Valamehr, PhD MBA, Vice President, Cancer Immunotherapy, **Fate Therapeutics Inc**

#### UCART "OFF-THE-SHELF" ALLOGENEIC PRODUCTS

David Sourdive, Vice President of Corporate Development, **Collectis**



# AGENDA DAY 1 Continued

## TARGETING, CONTROL & SCALABILITY



14:50 – 15:30 **ARMING NY-ESO-1-SPECIFIC TCR-T CELLS TO OVERCOME THE SUPPRESSIVE TUMOR MICROENVIRONMENT**

Neil Sheppard, Head External Co-operations & Early Development Leader, Oncology Cell Therapy, **GSK**

15:30 – 16:00 **NETWORKING BREAK & POSTER PRESENTATIONS**

16:00 – 16:35 **NOVEL APPROACHES TO GENE ENGINEERING: THE POTENTIAL OF CRISPR TO INCREASE EFFICACY OF CELL THERAPIES**

Yangbing Zhao, Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the **University of Pennsylvania**

16:35 -17:10 **KEYNOTE: NEXT GENERATION CELLULAR THERAPY - RED VS WHITE**

David Epstein, Chairman, **Rubius Therapeutics & Executive Partner Flagship Pioneering**

17:10-17:45 **IMPACT SOLID & HEMATOLOGIC CANCERS WITH SAME CAR-T: CYAD-01 AN INTEGRATED CLINICAL DEVELOPMENT**

Representative from Celyad

17:45-18:00 **CHAIR'S CLOSING REMARKS**

# AGENDA DAY 2

## TOXICITY, COMMERCIALIZATION, REGULATION & ALTERNATIVE CARs



9:00 – 9:15

### CHAIR'S OPENING REMARKS

9:15 – 10:00

### DEVELOPMENT OF ALLOGENEIC & AUTOLOGOUS BCMA-SPECIFIC CAR-T THERAPIES

Devon Shedlock, VP of Pre-clinical Development, **Poseida**

10:00 – 10:45

### PANEL: THE OBSTACLES TO PATIENT ACCESS: WHAT CONSIDERATIONS ARE NEEDED TO OVERCOME THE CHALLENGES OF EXPANDING CAR-T CELL THERAPY TO A GLOBAL PATIENT POPULATION?

Panellists:

Biren Mistry, Associate Director, **Celgene**

Gary C. Du Moulin, Ph.D., Adjunct Associate Professor of Regulatory Affairs, **Massachusetts College of Pharmacy and Health Sciences University**

10:45 – 11:15

### NETWORKING BREAK

#### STREAM 1: ALTERNATIVE CELL CONSTRUCTS

11:15 – 11:50

#### A NOVEL CLASS OF T CELL THERAPIES FOR SOLID TUMORS THAT UTILIZE THE FULL SIGNALLING POWER OF COMPLETE T CELL RECEPTORS (TCR)

Alfonso Quintas-Cardama, Chief Medical Officer, **TCR<sup>2</sup>**

11:50 – 12:25

#### ADOPTIVE $\gamma\delta$ T CELL & DRUG RESISTANT IMMUNOTHERAPY AS A STRATEGY FOR ELIMINATION OF RESIDUAL MALIGNANCY

Lawrence Lamb, Co-Founder, **Incysus**

#### STREAM 2: IMPLEMENTATION, REGULATION & PATIENT ACCESS

#### HOW TO REGULATE FOR A NEW FRONTIER IN MEDICAL INNOVATION: REGULATORY CONSIDERATIONS IN PROCESS DEVELOPMENT OF CELL THERAPY PRODUCTS

#### PARTNER SPOTLIGHT SESSION

Technologies to expand patient access to life-saving cell & gene therapies

Contact Ben Edwards to find out more by emailing [events@kisacoresearch.com](mailto:events@kisacoresearch.com) or by calling: +44 (0)20 3696 2924

12:25 – 13:55

### LUNCH & NETWORKING BREAK

13:55 – 14:30

#### CAR MACROPHAGES: NEXT GENERATION IMMUNOTHERAPY

Michael Klichinsky, Co-Founder, **CARMA Therapeutics**

#### STRATEGIC CONSIDERATIONS FOR THE DEVELOPMENT OF CAR-T CELL THERAPY

Biren Mistry, Associate Director, **Celgene**

14:30-15:05

#### CAR-T REGS: CARS FOR AUTOIMMUNE DISEASE

Stephane Boissel, CEO, **TxCell, France**

#### OBSTACLES TO PATIENT ACCESS: LESSONS LEARNED FROM A CARTILAGE REPAIR CELL THERAPY

Gary C. Du Moulin, Ph.D., M.P.H., Adjunct Associate Professor of Regulatory Affairs, **Massachusetts College of Pharmacy & Health Sciences University**

# AGENDA DAY 2 Continued

## TOXICITY, COMMERCIALIZATION, REGULATION & ALTERNATIVE CARs



15:05 – 15:40 **NETWORKING BREAK**

15:40 – 16:15 **BROADLY-SPECIFIC CYTOTOXIC T CELLS TARGETING MULTIPLE HIV ANTIGENS ARE EXPANDED FROM HIV & PATIENTS: IMPLICATIONS FOR IMMUNOTHERAPY**

Russell Cruz, Assistant Professor, [Children's National Medical Center](#)

16:15 – 17:00 **ROUNDTABLE SESSION**

- Can technology keep up with the pace of discovery?
- Strategies to improve patient outcomes
- Will CAR-T be overtaken by alternative CARs?
- Allogeneic vs Autologous: can off-the-shelf products compete?
- How will the supply-chain challenges be overcome?

17:00 **CHAIR'S CLOSING REMARKS**

## EVENT PARTNERS



### QuickSTAT

For 35 years, QuickSTAT has managed clinical trial logistics in more than 150 countries worldwide. With innovative solutions that offer complete end-to-end transportation services, your time and temperature-sensitive clinical research specimens, investigational drugs, and biologics are handled with unmatched attention, reliability and care. [www.quickstat.aero](http://www.quickstat.aero)



# LOCATION AND PRICING

Venue: Hilton Boston Dedham Hotel • 25 Allied Drive • Dedham, MA 0206



## PRICING INFORMATION

| PASS TYPE                                | EARLY BIRD 1<br>Before 12th January 2018 | EARLY BIRD 2<br>Before 9th February 2018 | STANDARD PRICING |
|------------------------------------------|------------------------------------------|------------------------------------------|------------------|
| <b>BIOPHARMA/BIOTECH</b>                 |                                          |                                          |                  |
| 2 day conference                         | \$1,299                                  | \$1,499                                  | \$1,699          |
| 2 day conference & commercialization day | \$1,998                                  | \$2,198                                  | \$2,398          |
| <b>VENDORS</b>                           |                                          |                                          |                  |
| 2 day conference                         | \$1,499                                  | \$1,699                                  | \$1,899          |
| 2 day conference & commercialization day | \$2,198                                  | \$2,398                                  | \$2,598          |
| <b>ACADEMIC / NON PROFIT / EMERGING</b>  |                                          |                                          |                  |
| 2 day conference                         | \$799                                    | \$799                                    | \$799            |
| 2 day conference & commercialization day | \$999                                    | \$999                                    | \$999            |
| <b>COMMERCIALIZATION DAY ONLY</b>        | \$999                                    | \$1,199                                  | \$1,399          |

### BOOK A TEAM TO SAVE MORE!

Industry Rates Only: Team discounts cannot be combined with any other discount or offer

#### Book a Team of 3+

Save an Additional 10% Off

#### Book a Team of 5+

Save an Additional 15% Off

#### Payment Terms:

- Please note that a \$79 processing fee will apply to any invoices requested.
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discount offers can be combined with any other offer
- Please view our Cancellation Policy
- QUESTIONS? Please email [events@kisacoresearch.com](mailto:events@kisacoresearch.com)